Vaxcyte Q3 loss smaller than estimates; plans VAX-31 filing in first half of 2028
Overview
U.S. vaccine developer's Q3 net loss was smaller than analyst expectations
Operating expenses rose 27% yr/yr, led by higher VAX-31 trial, manufacturing and personnel costs
VAX-31 met all prespecified primary endpoints in the pivotal Phase 3 OPUS-1 adult trial
Outlook
Company expects OPUS-2 and OPUS-3 Phase 3 trial results in first half of 2027
Vaxcyte plans to submit BLA for VAX-31 adult indication in first half of 2028
Company expects VAX-31 infant Phase 2 topline data by end of first half of 2027
Result Drivers
PCV PROGRAM SPENDING - Higher R&D and manufacturing costs for PCV programs, including VAX-31 Phase 3 trials, drove increased operating expenses
ADMINISTRATIVE COSTS - Growth in G&A headcount and professional services contributed to higher administrative expenses
OPUS-1 MILESTONE - VAX-31 met all prespecified primary endpoints and showed a safety profile similar to PCV20 and PCV21
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Net Loss | Beat | $297.06 mln | $310.72 mln (8 Analysts) |
Q3 Operating Expenses | $308.27 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Vaxcyte, Inc. is $121.00, about 99% above its November 3 closing price of $60.81
Reuters Recommended Reads
Nov 2 - Vertex Pharmaceuticals' Q3 revenue slightly beats estimates, outlook raised
Nov 3 - Amgen Q3 revenue beats expectations on higher volumes
Nov 2 - FDA to review uniQure's Huntington's gene therapy, decision due on May 2027
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)